Photo by Kev Costello on Unsplash.

See all articles

The Price of Women’s Empowerment

Femtech and the Paradox of Intimate Privacy

17.11.2026

“What female health needs through technology is Femtech.” (Ida Tin)

Ida Tin, the Danish entrepreneur behind Clue, captured the emergence of a new technological paradigm in women’s healthcare. Conceived in Berlin in 2011 and launched in 2013, Clue was the first mobile application designed for the systematic tracking of the menstrual cycle, transforming reproductive health into a continuous process of digital self-monitoring. Its success revealed an underserved market and laid the foundations for a distinct technological category, for which Tin coined the neologism “Femtech” in 2016.

The Rise of Femtech: Scope and Scale

Over recent years, the women’s health market has experienced an unprecedented expansion of Femtech apps, devices, and platforms. This industry encompasses startups developing digital solutions for more than ninety women’s health conditions and is projected to reach a value of approximately USD 60 billion by 2027. While menstrual-cycle tracking remains its most prominent application, Femtech currently extends to fertility management, pregnancy, postpartum care, menopause, sexual health, and AI-assisted diagnostics for conditions such as breast and cervical cancer. Crucially, these technologies rely on the collection and processing of highly sensitive personal data. Users routinely disclose biological indicators, reproductive histories, behavioral patterns, and other deeply intimate information that algorithms analyze to generate personalized health insights and recommendations.

Beyond its clever label uniting ‘female’ + ‘technology’, Femtech has played a pioneering role in addressing historical gender gaps in women’s health research through large-scale data collection. However, this is not just a story of clinical progress. By turning intimate data into decision-oriented knowledge, Femtech actively shapes how women exercise reproductive choice, bodily autonomy, and control over their well-being, while quietly challenging traditional expectations of privacy.

Historically, reproductive and menstrual information was typically shared only with healthcare professionals or trusted partners. Today, technology companies can collect, analyze, share, or sell the same data, creating detailed personal and collective profiles that may influence consumer behavior and reproductive choices. Importantly, much of this data is surrendered voluntarily through the acceptance of lengthy terms and conditions that few users read or fully understand.

At this point, it is easy to dismiss these concerns by asking: “Does it really matter if a tech company knows my cycle?” Examining the legal risks and digital rights implications reveals why the answer is a resounding yes.

Lights and Shadows

The Femtech industry is rooted in female empowerment, promising greater agency over health and bodily autonomy. Its rapid growth reflects the demand for reproductive self-determination, particularly in contexts where legal and socio-cultural barriers restrict access to healthcare. By requiring continuous user input, Femtech apps enable daily health tracking and generate valuable empirical data that support clinical diagnoses and research in female reproductive health. With one in three American women using these technologies, the resulting data aggregates offer unprecedented opportunities to improve understanding of women’s health and address longstanding gaps in medical knowledge.

Despite its transformative potential, the rapid growth of Femtech exposes significant vulnerabilities: without robust safeguards, these technologies can threaten user privacy and personal freedom. Although reproductive health data are inherently sensitive, they are routinely collected, shared, and commercialized, allowing an industry built on the rhetoric of female empowerment to turn women into commodities. Femtech apps continuously supply sensitive information to a digital ecosystem involving third parties, including data brokers, analytics firms, advertising agencies, and technology companies such as Google and Facebook. These data feed predictive algorithms that profile users, enabling targeted advertising and influencing sensitive decision-making processes. As a result, the health data of a woman experiencing infertility or severe gynecological conditions may lead to advertisements for costly fertility treatments, higher insurance premiums, increased credit rates, or even the denial of life insurance coverage.

Financial incentives compel application providers to maximize the extraction and aggregation of personal information within a digital economy where personal data functions as “the coin of the realm” and reproductive ones constitute one of the most commercially valuable asset classes. Empirical evidence demonstrates that these data transfers frequently occur without the user’s knowledge or meaningful comprehension. When platforms monetize or transfer this information without explicit, informed consent, they commit a direct infringement upon the right to “intimate privacy”, a specialized dimension of the traditional right to privacy that safeguards information touching upon the most intimate domain of personal autonomy, including reproductive choices, sexual practices and orientation, medical conditions, medication use, and personal habits.

This reveals the paradox of the right to intimate privacy within the Femtech ecosystem: the very technologies engineered to enhance women’s autonomy may simultaneously erode the sphere of intimate privacy upon which that autonomy depends. Resolving this paradox necessitates a regulatory framework capable of safeguarding that sphere, ensuring that women retain meaningful control over both their health and their data without compromising the effective enjoyment of their fundamental rights.

Regulating Femtech in the US and in the EU: A Comparative Perspective

Resolving this paradox requires an examination of how existing legal architectures attempt to safeguard intimate privacy. Across both sides of the Atlantic, legal systems address reproductive data through distinct regulatory philosophies; yet both the United States (US) and the European Union (EU) reveal notable regulatory limitations.

In the US, the implications of Femtech have become deeply concerning. Following the Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization, which overturned Roe v. Wade and returned abortion governance to individual states, the risk of surveillance and criminalization of reproductive choices has intensified. In “trigger states”, law enforcement authorities may compel digital platforms to disclose users’ intimate digital records as primary evidence in investigations relating to reproductive healthcare.

This vulnerability reflects the structural absence of a comprehensive federal data privacy law. Unlike the EU’s unified framework under the General Data Protection Regulation (GDPR), US privacy regulation remains highly fragmented across federal and state jurisdictions. Within the federal sphere, the Federal Trade Commission (FTC) relies primarily on its consumer protection powers under Section 5 of the FTC Act to address unfair or deceptive practices, while the Food and Drug Administration (FDA) exercises jurisdiction only over the rare Femtech apps cleared as Class II medical devices. The principal federal health privacy framework, however, remains the Health Insurance Portability and Accountability Act (HIPAA), enforced by the Department of Health and Human Services.

Although HIPAA encompasses “Protected Health Information” (PHI) under its Privacy Rule (45 CFR Part 164, Subpart E), 45 CFR § 160.103 strictly confines its scope to “covered entities” – namely, healthcare providers, health plans, and healthcare clearinghouses – and their business associates. Because most direct-to-consumer Femtech apps operate outside these clinical relationships, generally being classified as Health and Fitness apps at Google Play Store, the reproductive data they generate fall entirely outside HIPAA’s protective perimeter. In short, health data created outside traditional clinical settings remains virtually unregulated at the federal level, leaving them subject to a fragmented patchwork of federal enforcement mechanisms and state privacy laws, while recent efforts to strengthen federal privacy protections have encountered significant judicial hurdles.

Across the Atlantic, the GDPR has emerged as the EU’s principal legal response to these privacy risks. However, important regulatory gaps persist within the European legal framework. At the foundational level, intimate data collected by Femtech apps are not expressly recognized as a distinct special category under Article 9(1) GDPR. Although such data may fall within the notion of “data concerning health”, the Regulation does not expressly reconcile that category with “data concerning sex life”. Yet Femtech apps routinely process an inseparable combination of health, medical, sexual, and lifestyle information – a complex composite capable of revealing deeply sensitive attributes, including religious and political views, or sexual orientation.

This classification ambiguity is further compounded by structural loopholes under the Medical Device Regulation (MDR) (Regulation (EU) 2017/745). While Femtech apps intended for conception control qualify as medium-to-high-risk medical devices, classification hinges strictly on the manufacturer’s declared “intended purpose”. By marketing their products as “lifestyle” or “wellness” tools, developers routinely evade the stricter conformity assessments applicable to medical devices, despite offering functionalities that are substantively medical.

As a result, processing relies primarily on user consent, raising fundamental questions regarding its legal validity under the GDPR. Empirical evidence suggests that privacy policies are often unavailable upon initial access, consent is frequently presented through non-negotiable “take-it-or-leave-it” terms, and app gratuity forces users to surrender personal data as the price for access to essential services. Under these conditions, the voluntariness of consent is deeply compromised, as women frequently prioritize immediate reproductive health needs over a fully informed assessment of privacy risks. Moreover, upon installation, these applications activate embedded third-party trackers, enabling routine data harvesting that far exceeds what is necessary for core functionalities and directly violating the GDPR’s data minimization principle under Article 5(1)(c).

This internal enforcement gap persists under the Artificial Intelligence Act (Regulation (EU) 2024/1689). While Article 6 classifies AI systems incorporated into MDR-regulated medical devices as “high-risk” – triggering enhanced compliance obligations – it preserves the MDR’s underlying logic: because high-risk status depends on the manufacturer’s declared intended purpose, Femtech apps marketed as “lifestyle” or “wellness” tools fall entirely outside the high-risk regime.

These domestic European vulnerabilities assume an even greater significance in the context of transatlantic data transfers. The majority of leading Femtech companies are headquartered in the US, characterized by differing interpretations of fundamental rights and varying data protection standards. Transatlantic transfers of intimate data to US-based servers consequently expose European users to a jurisdiction lacking comprehensive federal privacy legislation and marked by heightened surveillance risks.

Ultimately, these two legal frameworks present two distinct yet equally insufficient regulatory responses to the challenges of Femtech. Whether through the US market-based system lacking a general privacy law or the strict, rights-oriented framework of the EU, both regimes ultimately seem to fail to resolve the paradox of intimate privacy, exposing broader structural failures regarding the protection of women’s autonomy within an increasingly data-driven healthcare ecosystem.

Conclusion: Intimate Privacy as a Collective Responsibility

The comparison between the US and the EU suggests that, while comprehensive privacy legislation remains essential, protecting reproductive autonomy also requires addressing the structural conditions under which intimate data are collected, shared, and commercialised. Effective safeguards therefore demand a coordinated response from policymakers, regulators, industry, and civil society.

In the US, stronger reproductive privacy protections need not depend solely on expanding HIPAA. Targeted state legislation, such as California’s Assembly Bill 254 (2023), together with FTC enforcement actions against Flo Health and Premom, demonstrates how this legislation and regulatory oversight can strengthen reproductive privacy protections and limit the commercial exploitation of reproductive data without awaiting comprehensive federal reform. Accountability should extend throughout the commercial ecosystem, including advertisers, analytics firms, and data brokers, with enforceable limits on the sale and secondary use of reproductive data.

In the EU, this objective is pursued primarily through effective enforcement of the GDPR across the data-processing chain. Principles such as data minimisation, purpose limitation, and data protection by design and by default help restrict excessive collection, incompatible secondary uses, and unlawful disclosures. These obligations are reinforced by more specific restrictions on data-driven advertising, including Article 26(3) DSA, which prohibits online platforms from presenting advertisements based on profiling using special categories of personal data under Article 9(1) GDPR.

Across both jurisdictions, an effective framework should protect both disclosed and inferred reproductive information, constrain unnecessary collection and secondary uses, and provide accessible remedies, including in cases of cross-border processing. Protection should follow intimate information throughout the data economy rather than diminish once it leaves the original Femtech provider. Regulation alone, however, cannot address all the challenges identified in this study. App distribution platforms could also require developers to meet robust privacy standards as a condition of inclusion and give greater weight to user reports of privacy breaches and other rights violations when ranking or promoting applications.

These measures are important because Femtech highlights another privacy paradox: users may value the convenience and empowerment offered by self-monitoring technologies while remaining their concerns about the collection, sharing, and monetisation of intimate data. Rather than reflecting individual choices alone, this tension stems from a structural asymmetry between users and commercial actors capable of exploiting personal information at scale.

Findings from the THELMA project also indicate that users may face difficulties accessing, exporting, and deleting their data, while often remaining unaware of how intimate information is inferred, monetised, and shared. Digital literacy initiatives should therefore enable women to understand these practices and exercise their rights effectively, without shifting responsibility for opaque data markets onto individuals. The future of Femtech depends on combining effective privacy protection with meaningful digital empowerment, ensuring that innovation strengthens rather than undermines reproductive autonomy.

Authors
Luana Mathias Souto

Luana is a postdoctoral research associate in law at the Centre for Protecting Women Online at the Open University in the UK. She is also the principal investigator of the Marie Skłodowska-Curie project THELMA (Reproductive Health under Algorithmic Surveillance).

View profile
Maria Vittoria Malinconi

Maria Vittoria is a PhD Candidate in Comparative Public Law at the University of Florence, where she obtained her master’s degree in law summa cum laude. She is currently a Visiting Researcher at King’s College London, following a previous research stay at Université Paris 1 Panthéon-Sorbonne and a research internship at the Institute of Legal Informatics and Judicial Systems of the Italian National Research Council (IGSG-CNR, Florence). Her primary research interest is cybersecurity law, alongside the constitutional implications of artificial intelligence, with a specific focus on Femtech and Deepfakes from a comparative perspective. Additionally, she is actively engaged in public outreach, delivering educational modules on AI and cybersecurity in upper secondary schools.

View profile
Print article

Leave a Reply

We very much welcome your engagement with posts via the comment function but you do so as a guest on our platform. Please note that comments are not published instantly but are reviewed by the Editorial Team to help keep our blog a safe place of constructive engagement for everybody. We expect comments to engage with the arguments of the corresponding blog post and to be free of ad hominem remarks. We reserve the right to withhold the publication of abusive or defamatory comments or comments that constitute hate speech, as well as spam and comments without connection to the respective post.

Submit your Contribution
We welcome contributions on all topics relating to international law and international legal thought. Please take our Directions for Authors and/or Guidelines for Reviews into account.You can send us your text, or get in touch with a preliminary inquiry at:
Subscribe to the Blog
Subscribe to stay informed via e-mail about new posts published on Völkerrechtsblog and enter your e-mail address below.